|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM063566885 |
| 003 |
DE-627 |
| 005 |
20231221223946.0 |
| 007 |
tu |
| 008 |
231221s1984 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0212.xml
|
| 035 |
|
|
|a (DE-627)NLM063566885
|
| 035 |
|
|
|a (NLM)6379678
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Armstrong, R D
|e verfasserin
|4 aut
|
| 245 |
1 |
2 |
|a A comparison of indoprofen and indomethacin in the treatment of ankylosing spondylitis
|
| 264 |
|
1 |
|c 1984
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 20.09.1984
|
| 500 |
|
|
|a Date Revised 21.11.2013
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a A double-blind, crossover trial was carried out to compare the effectiveness and tolerance of indoprofen with indomethacin in the treatment of ankylosing spondylitis. Nineteen patients entered the study and 1 was withdrawn for reasons unrelated to therapy. Patients received 4-weeks' treatment in random order, with 200 mg indoprofen 4-times daily and 25 mg indomethacin 4-times daily. Most subjective and objective clinical measurements of disease activity showed a comparable degree of improvement with either drug although few statistically significant changes were observed. There was no statistically significant difference between treatments and, although gastro-intestinal side-effects occurred more commonly with indoprofen, patients known to be intolerant of indomethacin had been excluded from this trial
|
| 650 |
|
4 |
|a Clinical Trial
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Randomized Controlled Trial
|
| 650 |
|
7 |
|a Phenylpropionates
|2 NLM
|
| 650 |
|
7 |
|a Indoprofen
|2 NLM
|
| 650 |
|
7 |
|a CPE46ZU14N
|2 NLM
|
| 650 |
|
7 |
|a Indomethacin
|2 NLM
|
| 650 |
|
7 |
|a XXE1CET956
|2 NLM
|
| 700 |
1 |
|
|a Laurent, R
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Panayi, G S
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC)
|d 1995
|g 3(1984), 10 vom: 20., Seite 637-41
|w (DE-627)NLM023961570
|
| 773 |
1 |
8 |
|g volume:3
|g year:1984
|g number:10
|g day:20
|g pages:637-41
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_31
|
| 912 |
|
|
|a GBV_ILN_39
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_121
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 3
|j 1984
|e 10
|b 20
|h 637-41
|